Skip Navigation LinksHome > January 2011 - Volume 17 - Issue 1 > Therapy with anti‐TNFα antibody enhances number and function...
Inflammatory Bowel Diseases:
doi: 10.1002/ibd.21308
Original Clinical Articles

Therapy with anti‐TNFα antibody enhances number and function of Foxp3+ regulatory T cells in inflammatory bowel diseases

Boschetti, Gilles1,2; Nancey, Stéphane1,2; Sardi, Fatima1; Roblin, Xavier3; Flourié, Bernard1,2; Kaiserlian, Dominique1

Collapse Box

Abstract

Background:: Inflammatory bowel diseases (IBDs) are associated with up‐regulation of TNFα, hyperactivation of proinflammatory effector T cells (Teffs) and inefficient control by regulatory CD4+CD25+Foxp3+ T cells (Tregs). The aim of this prospective study was to investigate the short‐term impact of treatment of IBD patients with anti‐TNFα antibodies (infliximab or adalimumab) on the frequency, phenotype, and suppressive function of Tregs.

Methods:: Active IBD patients including 16 with Crohn's disease and 9 with ulcerative colitis were treated with anti‐TNFα mAb. PBMCs were harvested immediately before and 2 weeks after the first injection. The frequency and phenotype of circulating CD4+CD25+Foxp3+ Tregs were analyzed by flow cytometry, and their suppressive function was assessed by the ability of purified CD4+CD25+CD127 Tregs to inhibit the proliferation of allogenic CD4+CD25 Teffs.

Results:: CD4+CD25+Foxp3+ Treg frequency was significantly lower in active IBD patients than in controls (2.8% ± 0.4% vs. 4.6% ± 0.6%, respectively; P = 0.01). On day 14 following the first anti‐TNFα infusion, the frequency of circulating Tregs was significantly enhanced in IBD patients (4.0% ± 0.5% vs. 2.8% ± 0.4%, before treatment; P = 0.001), with a 2‐ to 3‐fold increase in the intensity of Foxp3 expression. In addition, infliximab treatment enhanced the suppressive function of circulating Tregs, as shown by inhibition of Teff proliferation at a 1:8 Treg/Teff ratio (28% ± 5% vs. 66% ± 10%, after treatment; P = 0.04).

Conclusions:: These data demonstrate that anti‐TNFα treatment of active IBD rapidly enhances the frequency of functional Foxp3+ Tregs in blood and potentiates their suppressive function. This indicates that Treg potentiation may represent an unanticipated outcome of anti‐TNFα biotherapy in IBD. (Inflamm Bowel Dis 2011;)

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.